Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total value of $1,442,820.00. Following the sale, the director directly owned 366,682 shares in the company, valued at approximately $88,176,020.54. This represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Stock Performance
Jazz Pharmaceuticals stock opened at $244.17 on Tuesday. The company has a market cap of $15.34 billion, a PE ratio of -12,202.40, a P/E/G ratio of 0.21 and a beta of 0.32. The company has a fifty day moving average price of $229.26 and a two-hundred day moving average price of $195.95. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $246.07.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter. Research analysts expect that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on JAZZ shares. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Barclays upped their target price on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an "overweight" rating in a report on Wednesday, May 27th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Morgan Stanley reissued an "overweight" rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Finally, Leerink Partners boosted their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an "outperform" rating in a research report on Wednesday, April 22nd. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $245.94.
Get Our Latest Research Report on Jazz Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $36,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $38,000. Westpac Banking Corp bought a new position in Jazz Pharmaceuticals in the 1st quarter worth approximately $51,000. Leonteq Securities AG acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $50,000. Finally, Root Financial Partners LLC increased its position in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company's stock valued at $56,000 after acquiring an additional 89 shares during the period. Institutional investors own 89.14% of the company's stock.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
